SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Nordin Joel Z.)
 

Sökning: WFRF:(Nordin Joel Z.) > Extracellular vesic...

  • Liu, JiaqiUniv Sydney, Fac Med & Hlth, Sydney Pharm Sch, Sydney, Australia (författare)

Extracellular vesicles as the next-generation modulators of pharmacokinetics and pharmacodynamics of medications and their potential as adjuvant therapeutics

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • John Wiley & Sons,2024
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-537588
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-537588URI
  • https://doi.org/10.1002/ctm2.70002DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:159337056URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:for swepub-publicationtype

Anmärkningar

  • Background and main body Pharmacokinetics (PK) and pharmacodynamics (PD) are central concepts to guide the dosage and administration of drug therapies and are essential to consider for both healthcare professionals and researchers in therapeutic planning and drug discovery. PK/PD properties of a drug significantly influence variability in response to treatment, including therapeutic failure or excessive medication-related harm. Furthermore, suboptimal PK properties constitute a significant barrier to further development for some candidate treatments in drug discovery. This article describes how extracellular vesicles (EVs) affect different aspects of PK and PD of medications and their potential to modulate PK and PD properties to address problematic PK/PD profiles of drugs. We reviewed EVs' intrinsic effects on cell behaviours and medication responses. We also described how surface and cargo modifications can enhance EV functionalities and enable them as adjuvants to optimise the PK/PD profile of conventional medications. Furthermore, we demonstrated that various bioengineering strategies can be used to modify the properties of EVs, hence enhancing their potential to modulate PK and PD profile of medications.Conclusion This review uncovers the critical role of EVs in PK and PD modulation and motivates further research and the development of assays to unfold EVs' full potential in solving PK and PD-related problems. However, while we have shown that EVs play a vital role in modulating PK and PD properties of medications, we postulated that it is essential to define the context of use when designing and utilising EVs in pharmaceutical and medical applications.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Nordin, Joel Z.Karolinska Inst, Dept Lab Med, Div Biomol & Cellular Med, Div Clin Immunol, Huddinge, Sweden (författare)
  • McLachlan, Andrew J.Univ Sydney, Fac Med & Hlth, Sydney Pharm Sch, Sydney, Australia (författare)
  • Chrzanowski, WojciechUniv Sydney, Fac Med & Hlth, Sydney Pharm Sch, Sydney, Australia.;Karolinska Inst, Dept Lab Med, Div Biomol & Cellular Med, Div Clin Immunol, Huddinge, Sweden.;Uppsala Univ, Dept Mat Sci & Engn, Div Biomed Engn, Uppsala, Sweden (författare)
  • Univ Sydney, Fac Med & Hlth, Sydney Pharm Sch, Sydney, AustraliaKarolinska Inst, Dept Lab Med, Div Biomol & Cellular Med, Div Clin Immunol, Huddinge, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Clinical and Translational Medicine: John Wiley & Sons14:82001-1326

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy